Should bipolar disorder treatment be modified depending on staging?

Expert Review of Neurotherapeutics

Volumn 17, Issue 2, 2017, Pages 93-95

  Passos, Ives Cavalcante ^a   Kapczinski, Flávio ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

bipolar disorder; cognitive impairment; functional impairment; Staging; treatment refractoriness

Indexed keywords

BIPOLAR DISORDER; BRAIN FUNCTION; COGNITIVE BEHAVIORAL THERAPY; EDITORIAL; FUNCTIONAL DISEASE; HUMAN; MANIA; MOOD DISORDER; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SOCIAL INTERACTION; SYSTEMATIC REVIEW (TOPIC); VERBAL MEMORY;

EID: 85006846921     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1080/14737175.2017.1268532     Document Type: Editorial

References (34)

1. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder:update 2013. Bipolar Disord. 2013;15:1–44.​
2. Passos IC, Mwangi B, Vieta E, et al. Areas of controversy in neuroprogression in bipolar disorder. Acta Psychiatr Scand. 2016;134:91–103.•• This is an interesting review regarding neuroprogression in bipolar disorder. It reports neuroimaging and clinical studies supporting this hypothesis.
3. Samalin L, de Chazeron I, Vieta E, et al. Residual symptoms and specific functional impairments in euthymic patients with bipolar disorder. Bipolar Disord. 2016;18:164–173.
4. De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression:a systematic review and meta-analysis. J Psychopharmacol. 2012;26:603–617.
5. Kapczinski F, Dias VV, Kauer-Sant’Anna M, et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother. 2009;9:957–966.•• One of the first studies to propose a clinical staging in bipolar disorder.
6. Berk M, Conus P, Lucas N, et al. Setting the stage:from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 2007;9:671–678.
7. Rosa AR, Magalhães PVS, Czepielewski L, et al. Clinical staging in bipolar disorder:focus on cognition and functioning. J Clin Psychiatry. 2014;75:e450–e456.• This interesting clinical study showed a progressive functional decline from stage I through stage IV of bipolar disorder.
8. Da Costa SC, Passos IC, Lowri C, et al. Refractory bipolar disorder and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry. 2015;70:103–110.
9. Swann AC, Bowden CL, Calabrese JR, et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry. 1999;156:1264–1266.
10. Scott J, Paykel E, Morriss R, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders:randomised controlled trial. Br J Psychiatry. 2006;188:313–320.
11. Berk M, Brnabic A, Dodd S, et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord. 2011;13:87–98.
12. Obrocea GV, Dunn RM, Frye MA, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry. 2002;51:253–260.
13. Colom F, Reinares M, Pacchiarotti I, et al. Has number of previous episodes any effect on response to group psychoeducation in bipolar patients? A 5-year follow-up post hoc analysis. Acta Neuropsychiatr. 2010;22:50–53.
14. Reinares M, Colom F, Rosa AR, et al. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. J Affect Disord. 2010;123:81–86.
15. Goi PD, Bücker J, Vianna-Sulzbach M, et al. Pharmacological treatment and staging in bipolar disorder:evidence from clinical practice. Rev Bras Psiquiatr (São Paulo, Brazil). 1999;37:121–125.
16. Baldessarini RJ, Tondo L, Hennen J., Treatment-latency and previous episodes:relationships to pretreatment morbidity and response to maintenance treatment in bipolar I and II disorders. Bipolar Disord. 2003;5:169–179.
17. Berghöfer A, Alda M, Adli M, et al. Long-term effectiveness of lithium in bipolar disorder:a multicenter investigation of patients with typical and atypical features. J Clin Psychiatry. 2008;69:1860–1868.
18. Rybakowski JK. Response to lithium in bipolar disorder:clinical and genetic findings. ACS Chem Neurosci. 2014;5:413–421.
19. Tohen M, Hennen J, Zarate CM, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000;157:220–228.
20. Torrent C, Bonnin C, Del M, et al. Efficacy of functional remediation in bipolar disorder:a multicenter randomized controlled study. Am J Psychiatry. 2013;170:852–859.• This is an interesting study that proposed a new treatment approach called functional remediation for patients with bipolar disorder and functional impairment.
21. Bonnin CM, Torrent C, Arango C, et al. Functional remediation in bipolar disorder:1-year follow-up of neurocognitive and functional outcome. Br J Psychiatry. 2016;208:87–93.
22. Bonnin CM, Reinares M, Martínez-Arán A, et al. Effects of functional remediation on neurocognitively impaired bipolar patients:enhancement of verbal memory. Psychol Med. 2016;46:291–301.
23. Li X-B, Tang Y-L, Wang C-Y, et al. Clozapine for treatment-resistant bipolar disorder:a systematic review. Bipolar Disord. 2014;3:235–247.
24. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry. 2006;11:227–240.
25. Poon SH, Sim K, Sum MY, et al. Evidence-based options for treatment-resistant adult bipolar disorder patients. Bipolar Disord. 2012;14:573–584.
26. Flanagan RJ. Side effects of clozapine and some other psychoactive drugs. Curr Drug Saf. 2008;3:115–122.
27. Young AH, Gallagher P, Watson S, et al. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 2004;29:1538–1545.
28. Miskowiak KW, Ehrenreich H, Christensen EM, et al. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder:a double-blind, randomized, placebo-controlled phase 2 trial. J Clin Psychiatry. 2014;75:1347–1355.
29. Naismith SL, Redoblado-Hodge MA, Lewis SJG, et al. Cognitive training in affective disorders improves memory:a preliminary study using the NEAR approach. J Affect Disord. 2010;121:258–262.
30. Demant KM, Vinberg M, Kessing LV, et al. Effects of short-term cognitive remediation on cognitive dysfunction in partially or fully remitted individuals with bipolar disorder:results of a randomised controlled trial. Scott JG, editor. PLoS One. 2015;10:e0127955.
31. Miskowiak KW, Carvalho AF, Vieta E, et al. Cognitive enhancement treatments for bipolar disorder:a systematic review and methodological recommendations. Eur Neuropsychopharmacol. 2016;26:1541–1561.
32. Alda M, Kapczinski F. Staging model raises fundamental questions about the nature of bipolar disorder. J Psychiatry Neurosci. 2016;41:291–293.
33. Alda M, Kapczinski F. Concepts and misconceptions regarding clinical staging models:author response. J Psychiatry Neurosci. 2016;41:E84–E85.
34. Shah J, Scott J. Concepts and misconceptions regarding clinical staging models. J Psychiatry Neurosci. 2016;41:E83–E84.